Nabla Bio

Nabla Bio company information, Employees & Contact Information

Explore related pages

Related company profiles:

We develop AI and wet-lab technologies that enable the rational design of developable, selective, and functional drugs against previously undruggable targets. To maximize the patient impact of our platform, we collaborate with leading pharmaceutical companies, including AstraZeneca, Bristol Myers Squibb and Takeda, to expand their pipelines with high-quality drug candidates. If successful we could double the number of disease-relevant drug targets the industry advances for drug development. Since launching in 2021 we have raised $37 million with the backing of leading investors, including Radical Ventures, Khosla Ventures and Zetta Venture Partners. Our technical team is based in Cambridge, Massachusetts and continues to recruit top machine learning and synthetic biology talent. For more information check out the Careers section of our website at www.nabla.bio.

Company Details

Employees
21
Address
840 Memorial Dr, Cambridge,massachusetts 02139,united States
Industry
Biotechnology
Keywords
Function Health.
HQ
Cambridge, Massachusetts
Looking for a particular Nabla Bio employee's phone or email?

Nabla Bio Questions

News

Takeda turns to AI drug designer for $1B biobucks deal after whittling down R&D focus - Fierce Biotech

Takeda turns to AI drug designer for $1B biobucks deal after whittling down R&D focus Fierce Biotech

US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership - Reuters

US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership Reuters

Nabla Bio expands Takeda collab for protein therapeutics - Pharmaceutical Technology

Nabla Bio expands Takeda collab for protein therapeutics Pharmaceutical Technology

Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics - BioSpace

Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics BioSpace

US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership - AOL.com

US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership AOL.com

Takeda expands de novo protein research by signing second deal with AI specialist Nabla Bio - Endpoints News

Takeda expands de novo protein research by signing second deal with AI specialist Nabla Bio Endpoints News

Takeda Pharmaceutical Company (TAK) Signs a Research Partnership with Nabla Bio - Yahoo Finance

Takeda Pharmaceutical Company (TAK) Signs a Research Partnership with Nabla Bio Yahoo Finance

AI-based protein discovery start-up strikes a second deal with Takeda - Chemical & Engineering News

AI-based protein discovery start-up strikes a second deal with Takeda Chemical & Engineering News

Nabla Bio Enters $1 Billion Multi-Year Research Collaboration with Takeda - Pharmaceutical Executive

Nabla Bio Enters $1 Billion Multi-Year Research Collaboration with Takeda Pharmaceutical Executive

Takeda and Nabla Bio Expand AI Therapeutics Collaboration - Precedence Research

Takeda and Nabla Bio Expand AI Therapeutics Collaboration Precedence Research

Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact - Benzinga

Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact Benzinga

Nabla Bio and Takeda enter new research collaboration - BioWorld MedTech

Nabla Bio and Takeda enter new research collaboration BioWorld MedTech

AI conjures up potential new antibody drugs in a matter of months - Science | AAAS

AI conjures up potential new antibody drugs in a matter of months Science | AAAS

Takeda Makes $1B+ AI Bet With Nabla to Build Out Early Pipeline - BioSpace

Takeda Makes $1B+ AI Bet With Nabla to Build Out Early Pipeline BioSpace

Test-Time Scaling Improves Speed and Success of AI-Based Antibody Design - Genetic Engineering and Biotechnology News

Test-Time Scaling Improves Speed and Success of AI-Based Antibody Design Genetic Engineering and Biotechnology News

Nabla Bio signs second Takeda collaboration to advance ai-driven design of protein therapeutics - MarketScreener

Nabla Bio signs second Takeda collaboration to advance ai-driven design of protein therapeutics MarketScreener

Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox | GEN Biotechnology - Mary Ann Liebert, Inc.

Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox | GEN Biotechnology Mary Ann Liebert, Inc.

The Endpoints Slack interview: AI bio backer Dylan Reid on techbio's original sin - Endpoints News

The Endpoints Slack interview: AI bio backer Dylan Reid on techbio's original sin Endpoints News

Nabla Bio and Takeda expand AI-powered drug design partnership in multi-year, billion-dollar deal - IndiaMedToday

Nabla Bio and Takeda expand AI-powered drug design partnership in multi-year, billion-dollar deal IndiaMedToday

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs - Endpoints News

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs Endpoints News

With all eyes on AI-protein design, Nabla says it can model therapeutic antibodies - FirstWord Pharma

With all eyes on AI-protein design, Nabla says it can model therapeutic antibodies FirstWord Pharma

OpenAI-backed startup releases new AI models, claiming top performance in making antibodies - Endpoints News

OpenAI-backed startup releases new AI models, claiming top performance in making antibodies Endpoints News

Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda for Generative Protein Design - Business Wire

Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda for Generative Protein Design Business Wire

Maxion ties the Knot on a $72M round for GPCR-targeting antibodies - FirstWord Pharma

Maxion ties the Knot on a $72M round for GPCR-targeting antibodies FirstWord Pharma

These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company

These 10 biotech companies are changing how we discover new drugs and treat complex diseases Fast Company

Nabla Bio Secures $26 Million Funding Boost to Drive Protein Design Innovations - SynBioBeta

Nabla Bio Secures $26 Million Funding Boost to Drive Protein Design Innovations SynBioBeta

Nabla Bio secures $26m in Series A funding round - Yahoo Finance

Nabla Bio secures $26m in Series A funding round Yahoo Finance

Exclusive: Harvard startup raises $26M, strikes three pharma partnerships for AI antibody design - Endpoints News

Exclusive: Harvard startup raises $26M, strikes three pharma partnerships for AI antibody design Endpoints News

Fierce Pharma Asia—High-dollar licensing deals; Takeda's AI drug design pact; and the finale of Novo vs. KBP - Fierce Pharma

Fierce Pharma Asia—High-dollar licensing deals; Takeda's AI drug design pact; and the finale of Novo vs. KBP Fierce Pharma

The Petri Dish: Nabla Bio nabs $26M, X4 gets capital infusion - The Business Journals

The Petri Dish: Nabla Bio nabs $26M, X4 gets capital infusion The Business Journals

Direct-To-Consumer Trends | PharmExec - Pharmaceutical Executive

Direct-To-Consumer Trends | PharmExec Pharmaceutical Executive

Best Workplaces for Innovators 2024: Biotech - Fast Company

Best Workplaces for Innovators 2024: Biotech Fast Company

The 3 Waves of AI in Bio - NFX

The 3 Waves of AI in Bio NFX

Harvard spinout Nabla Bio nabs $11M for AI-driven antibody design - Fierce Biotech

Harvard spinout Nabla Bio nabs $11M for AI-driven antibody design Fierce Biotech

Nabla Bio raises $11M for an "end-to-end" antibody design platform - TechCrunch

Nabla Bio raises $11M for an "end-to-end" antibody design platform TechCrunch

[Interview] DeepMind predicted proteins. A Korean startup says it’s designing the future of antibodies. - koreabiomed.com

[Interview] DeepMind predicted proteins. A Korean startup says it’s designing the future of antibodies. koreabiomed.com

Harvard spinout Nabla Bio lands $11M to bring AI technology to antibody design - MedCity News

Harvard spinout Nabla Bio lands $11M to bring AI technology to antibody design MedCity News

How generative AI is building better antibodies - Nature

How generative AI is building better antibodies Nature

PNC’s Janet Nabla petitions CID to probe Apasera, Moses Baah for alleged stealing - CitiNewsroom.com

PNC’s Janet Nabla petitions CID to probe Apasera, Moses Baah for alleged stealing CitiNewsroom.com

Takeda Expands AI Drug Discovery Partnership with U.S. Biotech Firm Nabla Bio in $1 Billion Deal - Brand Icon Image

Takeda Expands AI Drug Discovery Partnership with U.S. Biotech Firm Nabla Bio in $1 Billion Deal Brand Icon Image

Top Nabla Bio Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant